Pharmaceutical Composition of a Topical Dosage form of Itraconazole for the Treatment of Athlete's Foot
DOI:
https://doi.org/10.61841/50efqd87Keywords:
Athlete’s foot, fungal infection, scaly rash, itching, stinging, Trychophytonrubrum, itraconazole, ergosterol, lanosterol 14α-demethylaseAbstract
Athlete’s foot is a cutaneous fungal infection that usually begins between the toes. It usually happens in people whose feet are very sweaty while confined in fitting shoes. Signs and symptoms of the athlete’s foot include a scaly rash which usually causes “itching, stinging and burning”. It is caused by the fungus "Trychophytonrubrum". In severe cases, the skin may blister (A collection of fluid below the top layer of skin i.e. epidermis). Many oral and topical treatments are available to cure Athlete's foot. Oral itraconazole (Mw~705.64 g, Melting Point~166.3°C, Weak base pKa~3.7) is the most commonly used antifungal drug in the treatment of Athlete's foot at the dose of 100 mg once-a-day for 30 days. The anti-fungal drug itraconazole is used to treat fungal infections in adults. Infection of the lungs, mouth or throat, toenails or fingernails includes infections in any part of the body. Some of the brands of itraconazole cannot be used for the treatment of fungal infections of the fingernails or toenails. Mechanistically, itraconazole inhibits the fungal-mediated synthesis of ergosterol, via inhibition of lanosterol 14α-demethylase. However, poor physicochemical attributes, interference of food, side-effects (Nausea, diarrohea, and hepatotoxicity) and lesser bioavailability (55%) alters the therapeutic efficacy of itraconazole. in present investigation, a pharmaceutical dermal cream of itraconazole was formulated by oil in water (O/w) emulsion method to improve skin penetration in the treatment of tineapedis infection. Among several chemical permeation enhancers, dimethyl sulfoxide was used in the pharmaceutical dermal cream of itraconazole to augment the penetration of drug in skin.
Downloads
References
[1] I. Rotta, M. F. Otuki, and C. J. Correr, “Athlete’s Foot,” in Evidence-Based Dermatology: Third Edition,
2014.
[2] V. Kaitlin, Z. Zinn, and R. Powers, “Macerated foot dermatitis related to occlusive footwear,” W. V. Med.
J., 2013.
[3] S. Monecke, C. Luedicke, P. Slickers, and R. Ehricht, “Molecular epidemiology of Staphylococcus aureus
in asymptomatic carriers,” Eur. J. Clin. Microbiol. Infect. Dis., 2009.
[4] S. Morrison, “Chronic laminitis: Foot management,” Veterinary Clinics of North America - Equine
Practice. 2010.
[5] G. F. Chan, S. Sinniah, T. I. N. T. Idris, M. S. A. Puad, and A. Z. A. Rahman, “Multiple rare opportunistic
and pathogenic fungi in persistent foot skin infection,” Pakistan J. Biol. Sci., 2013.
[6] M. N. Somchit, “Anti-fungal activity of Ardisia crispa (Thunb.) A.DC. against several fungi responsible for
athlete’s foot,” African J. Microbiol. Res., 2011.
[7] N. Kumar and S. Goindi, “Statistically designed nonionic surfactant vesicles for dermal delivery of
itraconazole: Characterization and in vivo evaluation using a standardized Tinea pedis infection model,”
Int. J. Pharm., 2014.
[8] N. Sun et al., “In vivo pharmacokinetics and in vitro antifungal activity of iodiconazole, a new triazole,
determined by microdialysis sampling,” Int. J. Antimicrob. Agents, 2013.
[9] J. A. Young, “Stearic Acid,” J. Chem. Educ., 2004.
[10] J. E. Nett and D. R. Andes, “Itraconazole,” in Kucers the Use of Antibiotics: A Clinical Review of
Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition, 2017.
[11] S. E. Bell-Syer, S. M. Khan, and D. J. Torgerson, “Oral treatments for fungal infections of the skin of the
foot,” Cochrane Database Syst. Rev., 2012.
[12] F. S. Buckner, B. M. Joubert, S. M. Boyle, R. T. Eastman, C. L. M. J. Verlinde, and S. P. T. Matsuda,
“Cloning and analysis of Trypanosoma cruzi lanosterol 14α-demethylase,” Mol. Biochem. Parasitol., 2003.
[13] M. Ilkit and M. Durdu, “Tinea pedis: The etiology and global epidemiology of a common fungal infection,”
Critical Reviews in Microbiology. 2015.
[14] J. W. Ely, S. Rosenfeld, and M. S. Stone, “Diagnosis and management of tinea infections,” Am. Fam.
Physician, 2014.
[15] S. Singh, M. Singh, C. B. Tripathi, M. Arya, and S. A. Saraf, “Development and evaluation of ultra-small
nanostructured lipid carriers: novel topical delivery system for athlete’s foot,” Drug Deliv. Transl. Res.,
2016.
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
